No Record Found
Sector
PharmaceuticalsOpen
₹4,950Prev. Close
₹4,994.6Turnover(Lac.)
₹773.51Day's High
₹4,984.3Day's Low
₹4,903.652 Week's High
₹5,99352 Week's Low
₹3,701Book Value
₹1,005.12Face Value
₹10Mkt Cap (₹ Cr.)
22,648.79P/E
32.31EPS
154.48Divi. Yield
3.31No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 45.75 | 45.75 | 45.75 | 45.75 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 4,171.66 | 3,549.79 | 3,161.55 | 2,818.66 |
Net Worth | 4,217.41 | 3,595.54 | 3,207.3 | 2,864.41 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 2,610.99 | 2,238.55 | 2,151.65 | 1,968.51 |
yoy growth (%) | 16.63 | 4.03 | 9.3 | 0.11 |
Raw materials | -948.03 | -797.74 | -792.4 | -739.68 |
As % of sales | 36.3 | 35.63 | 36.82 | 37.57 |
Employee costs | -403.67 | -361.06 | -364.51 | -314.29 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 772.89 | 668.72 | 642.49 | 547.91 |
Depreciation | -115 | -109.41 | -103.24 | -66.25 |
Tax paid | -160.33 | -171.11 | -133.36 | -187.84 |
Working capital | 385.47 | -980.02 | 712.61 | 190.64 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 16.63 | 4.03 | 9.3 | 0.11 |
Op profit growth | 17.35 | 24.37 | 14.44 | 43.29 |
EBIT growth | 14.55 | 4.66 | 19.15 | 41.55 |
Net profit growth | 23.1 | -2.26 | 41.39 | 6.91 |
| Particulars (Rupees in Crores.) | Nov-2009 | Nov-2008 | Nov-2007 | Nov-2006 | Nov-2005 |
|---|---|---|---|---|---|
Gross Sales | 772.27 | 681.7 | 676.69 | 770.59 | 702.34 |
Excise Duty | 0 | 0 | 0 | 60.4 | 54.15 |
Net Sales | 772.27 | 681.7 | 676.69 | 710.2 | 648.17 |
Other Operating Income | 24.37 | 22.89 | 0 | 0 | 0 |
Other Income | 71.05 | 278.01 | 343.07 | 59.59 | 41.06 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,799.5 | 92.81 | 4,33,763.77 | 564.22 | 0.89 | 4,511.27 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,417.5 | 67.82 | 1,70,489.23 | 696 | 0.47 | 2,660 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,728 | 59.24 | 1,26,435.85 | 597 | 0.16 | 2,707 | 249.83 |
Cipla Ltd CIPLA | 1,516.6 | 23.68 | 1,23,088.18 | 1,210.53 | 1.05 | 4,495.16 | 411.56 |
Dr Reddys Laboratories Ltd DRREDDY | 1,275.2 | 19.48 | 1,05,162.27 | 387.3 | 0.63 | 4,602.9 | 377.56 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Independent Director
MEENA GANESH
Managing Director
Meenakshi Nevatia
Director (Finance) & Chief Financial Officer
Amit Agarwal
Independent Director
L Krishnakumar
Independent Director
Sonia Singh
Executive Director
P. Rengan
Chairman (Non-Executive)
Pradip P Shah
Company Sec. & Compli. Officer
Prajeet Nair
The Capital 1802/1901 Plot-C70,
G Bl Bandra Kurla Cpx Bandra-E,
Maharashtra - 400051
Tel: 91-22-66932000
Website: http://www.pfizerindia.com
Email: contactus.india@pfizer.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 busine...
Read More
Reports by Pfizer Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.